Multiple myeloma patients to get NHS access to Amgen’s Kyprolis
The National Institute for Health and Care Excellence is backing routine NHS use of Amgen’s Kyprolis as an option for treating patients with multiple myeloma at first relapse. In a Final Appraisal Determination, the Institute has recommended the drug in combination with dexamethasone for adults with relapsed multiple myeloma (RMM) who have received one prior